Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.49 |
| ▸ | F10 | P00742 | 1/20 | 0.49 |
| ▸ | PLAU | P00749 | 1/20 | 0.49 |
| ▸ | PLAT | P00750 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 9/20 | 0.47 |
| ▸ | PPARD | Q03181 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19486307 | 0.94 | F2 (0.49) | F2F10PLAUPLATLTA4H | |
| SCHEMBL15149837 | 0.85 | PRSS1 (0.44) | F2F10PLAUPLATMAOB | |
| SCHEMBL15145194 | 0.84 | PRSS1 (0.47) | F2F10PLAUPLATMAOB | |
| SCHEMBL19486224 | 0.84 | PRSS1 (0.47) | F2F10PLAUPRSS1TMPRSS2 | |
| SCHEMBL19481642 | 0.83 | F2 (0.43) | F2F10PLAUPLATMAOB | |
| SCHEMBL1116009 | 0.80 | NPC1 (0.61) | LTA4HMAOBPPARDKMT2A | |
| SCHEMBL30084765 | 0.80 | NPC1 (0.61) | LTA4HMAOBPPARDKMT2A | |
| SCHEMBL16450867 | 0.79 | PLAU (0.45) | F2F10PLAUPLATMAOB | |
| SCHEMBL538994 | 0.79 | KMT2A (0.55) | LTA4HMAOBPPARDKMT2ACA12 | |
| SCHEMBL30231667 | 0.79 | MAOB (0.71) | MAOBPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170298057-A1 | DEUTERATED O-SULFATED BETA LACTAM HYDROXAMIC ACIDS AND DEUTERATED N- SULFATED BETA LACTAMS | ARIXA PHARMACEUTICALS, INC. | 2017-10-19 | — | — | US | disclosed |
| WO-2017180794-A1 | DEUTERATED O-SULFATED BETA-LACTAM HYDROXAMIC ACIDS AND DEUTERATED N-SULFATED BETA-LACTAMS | SKYLINE ANTIINFECTIVES, INC. (US) | 2017-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298057-A1 | DEUTERATED O-SULFATED BETA LACTAM HYDROXAMIC ACIDS AND DEUTERATED N- SULFATED BETA LACTAMS | DDOST, LBR, STS | F2 1548/4885F10 3332/4885PLAU 1445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.